EwingSarcoma
Conditions
Interventions
Treatment group:The intervention of this study is: the implementation of "spatiotemporal fractionated" whole lung irradiation using helical tomotherapy (TOMO) for patients with pulmonary metastases fr
Sponsors
Peking University Shougang Hospital
Eligibility
Sex/Gender
All
Age
6 Years to 34 Years
Inclusion criteria
Inclusion criteria: 1. Patients diagnosed with Ewing's sarcoma by histopathological examination. 2. Patients with pulmonary metastasis confirmed by imaging (CT/MRI/PET-CT), with or without pleural, vertebral, or other metastases (regardless of initial treatment or recurrence), who require whole-lung irradiation radiotherapy. 3. Age >= 6 years and = 3 months. 6. Adequate cardiopulmonary, hepatic, and renal function to tolerate radiotherapy, as assessed by the following criteria: FEV1 >= 50% of predicted value; NYHA cardiac functional class I–II; Liver and kidney function within normal limits or with mild abnormalities that, in the investigator’s judgment, do not preclude radiotherapy. 7. The patient or their legal representative provides informed consent and signs the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Previously received chest radiotherapy, and the multidisciplinary team (MDT) assessment determined that it is no longer safe to undergo this full lung irradiation. 2. Present with active pulmonary infection, uncontrolled large pleural effusion or pericardial effusion. 3. Suffering from severe interstitial lung disease or severely impaired lung function (FEV1 < 50% of the predicted value). 4. Affected by any unstable systemic diseases, including active infection, uncontrolled hypertension, severe arrhythmia, heart failure (NYHA cardiac function classification III-IV grade), etc. 5. Pregnant or lactating women. 6. Having a psychological state that cannot complete radiotherapy, such as fear, anxiety (assessed by the researcher and confirmed by a psychiatrist).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of Grade >=3 Acute Radiation Pneumonitis;Objective Response Rate (ORR);Disease Control Rate (DCR);Lung Progression-Free Survival (LPFS); | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall Survival (OS);Incidence of Acute Toxicities;Incidence of Late Toxicities;Safety of Combination Therapy (Incidence of Grade >=3 Adverse Events); | — |
Countries
china
Contacts
Public ContactYang Yuanyou
Peking University Shougang Hospital
Outcome results
None listed